Phase IB trial
Showing 1 - 25 of >10,000
Advanced Solid Tumor Trial in Shanghai (JS015, Toripalimab, Paclitaxel)
Not yet recruiting
- Advanced Solid Tumor
- JS015
- +10 more
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 17, 2023
Advanced Solid Tumors Trial (AK127 in combination with AK112)
Not yet recruiting
- Advanced Solid Tumors
- AK127 in combination with AK112
- (no location specified)
Jul 11, 2023
Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)
Recruiting
- Sarcoma
- Fluzoparib+ Dalpiciclib
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023
Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),
Recruiting
- Acute Gout
- Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
- +6 more
-
Wuhan, Hubei, China
- +2 more
Oct 17, 2022
Advanced Solid Tumors Trial (SHR-A2009 for injection ; Almonertinib Mesilate Tablets, SHR-A2009 for injection;Adebrelimab
Not yet recruiting
- Advanced Solid Tumors
- SHR-A2009 for injection ; Almonertinib Mesilate Tablets
- SHR-A2009 for injection;Adebrelimab Injection
- (no location specified)
Oct 17, 2023
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- (no location specified)
Jun 28, 2023
Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)
Recruiting
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2023
Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)
Not yet recruiting
- Breast Neoplasms
- Sindilimab
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiangCH
Nov 17, 2023
Heart Failure With Reduced Ejection Fraction Trial (AC01)
Not yet recruiting
- Heart Failure With Reduced Ejection Fraction
- (no location specified)
Jan 31, 2023
Bone Cancer Trial in Villejuif (regorafenib tablet)
Recruiting
- Bone Cancer
- regorafenib tablet
-
Villejuif, Ile De France, FranceGustave Roussy
Apr 13, 2023
NASH, NAFLD Trial in Hangzhou (GH509, Placebo)
Recruiting
- NASH
- NAFLD
- GH509
- Placebo
-
Hangzhou, Zhejiang, ChinaThe Affiliated Hospital of Hangzhou Normal University
Mar 26, 2023
Advanced Solid Tumor Trial (Adebrelimab, SHR-1802, Carboplatin/Cisplatin)
Not yet recruiting
- Advanced Solid Tumor
- Adebrelimab
- +3 more
- (no location specified)
Mar 20, 2023
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction (GEJ) Cancer
- T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- (no location specified)
Jun 7, 2023
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Melanoma Trial in Beijing (IBI363)
Not yet recruiting
- Melanoma
- IBI363
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Oct 7, 2023
Rheumatoid Arthritis Trial (VC005 tablets, VC005 Tablets Placebo)
Not yet recruiting
- Rheumatoid Arthritis
- VC005 tablets
- VC005 Tablets Placebo
- (no location specified)
May 24, 2023
Advanced Liver Cancer Trial in Chengdu (QL1706, QL1604, Bevacizumab)
Recruiting
- Advanced Liver Cancer
- QL1706
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Nov 1, 2022
Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with
Recruiting
- Inhibition of Autophagy Synergizes Anti-tumor Effect
- 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023
Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT
Not yet recruiting
- Unresectable Hepatocellular Carcinoma
- +3 more
- Lenvatinib/Pembrolizumab plus SBRT combinations
-
Taipei City, Taiawn, TaiwanNational Taiwan University Hospital
Jan 30, 2023
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)
Recruiting
- Non-hodgkin's Lymphoma
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Jan 12, 2023